PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
PDS Biotechnology (NASDAQ: PDSB), a late-stage immunotherapy company, announced that the National Cancer Institute (NCI) will present clinical data on PDS01ADC, their IL-12 fused antibody drug conjugate, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025.
The presentation, scheduled for April 29, 2025, will focus on alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy. The poster session, titled 'Immune Response to Therapies,' will be presented by Meghali Goswami, Postdoctoral Fellow at The National Institutes of Health.
PDS Biotechnology (NASDAQ: PDSB), un'azienda di immunoterapia in fase avanzata, ha annunciato che il National Cancer Institute (NCI) presenterà dati clinici su PDS01ADC, il loro coniugato di farmaco a base di anticorpo fusione IL-12, al prossimo American Association for Cancer Research (AACR) Annual Meeting 2025.
La presentazione, prevista per il 29 aprile 2025, si concentrerà sulle alterazioni nelle cellule staminali T periferiche simili a cellule della memoria in pazienti con tumori solidi avanzati trattati con terapia IL-12 mirata al tumore. La sessione poster, intitolata 'Risposta immunitaria alle terapie', sarà presentata da Meghali Goswami, ricercatrice post-dottorato presso i National Institutes of Health.
PDS Biotechnology (NASDAQ: PDSB), una empresa de inmunoterapia en etapa avanzada, anunció que el Instituto Nacional del Cáncer (NCI) presentará datos clínicos sobre PDS01ADC, su conjugado de fármaco anticuerpo fusionado IL-12, en la próxima Reunión Anual de la Asociación Americana para la Investigación del Cáncer (AACR) 2025.
La presentación, programada para el 29 de abril de 2025, se centrará en las alteraciones en las células madre T periféricas similares a la memoria en pacientes con tumores sólidos avanzados tratados con terapia IL-12 dirigida al tumor. La sesión de póster, titulada 'Respuesta inmune a las terapias', será presentada por Meghali Goswami, investigadora postdoctoral en los Institutos Nacionales de Salud.
PDS Biotechnology (NASDAQ: PDSB), 후기 면역 치료 회사,가 미국 국립 암 연구소(NCI)가 PDS01ADC, 그들의 IL-12 융합 항체 약물 결합체에 대한 임상 데이터를 다가오는 2025년 미국 암 연구 협회(AACR) 연례 회의에서 발표할 것이라고 발표했습니다.
2025년 4월 29일로 예정된 발표는 고급 고형 종양으로 치료받는 환자에서 말초 T 줄기 세포와 유사한 기억 세포의 변화에 초점을 맞출 것입니다. '치료에 대한 면역 반응'이라는 제목의 포스터 세션은 국립 보건원(NIH)의 박사후 연구원인 Meghali Goswami가 발표할 예정입니다.
PDS Biotechnology (NASDAQ: PDSB), une entreprise d'immunothérapie en phase avancée, a annoncé que le National Cancer Institute (NCI) présentera des données cliniques sur PDS01ADC, leur conjugué de médicament à base d'anticorps fusionné IL-12, lors de la prochaine Réunion Annuelle de l'Association Américaine pour la Recherche sur le Cancer (AACR) 2025.
La présentation, prévue pour le 29 avril 2025, se concentrera sur les altérations des cellules mémoire T-stem-like périphériques chez les patients atteints de tumeurs solides avancées traités par une thérapie IL-12 ciblant la tumeur. La session d'affiches, intitulée 'Réponse immunitaire aux thérapies', sera présentée par Meghali Goswami, chercheuse postdoctorale aux National Institutes of Health.
PDS Biotechnology (NASDAQ: PDSB), ein Unternehmen für Immuntherapie in der späten Phase, gab bekannt, dass das National Cancer Institute (NCI) klinische Daten zu PDS01ADC, ihrem IL-12-fusionierten Antikörper-Wirkstoff-Konjugat, auf dem bevorstehenden Jahrestreffen der American Association for Cancer Research (AACR) 2025 präsentieren wird.
Die Präsentation, die für den 29. April 2025 geplant ist, wird sich auf Veränderungen in peripheren T-Stammzellen-ähnlichen Gedächtniszellen bei Patienten mit fortgeschrittenen soliden Tumoren konzentrieren, die mit tumorzielender IL-12-Therapie behandelt werden. Die Poster-Session mit dem Titel 'Immunantwort auf Therapien' wird von Meghali Goswami, Postdoktorandin an den National Institutes of Health, präsentiert.
- Clinical data from NCI study of PDS01ADC accepted for presentation at major cancer research conference
- None.
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation
PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute (“NCI”) reporting clinical data on PDS01ADC, the Company’s IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
Details of the presentation are as follows:
Title: Alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy
Abstract: 5800 / 9
Session Type: Poster Session
Session Title: PO.CL06.10 - Immune Response to Therapies
Date and Time: April 29, 2025, 2:00 PM - 5:00 PM CT
Presenter: Meghali Goswami, Postdoctoral Fellow, The National Institutes of Health
About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.
For more information, please visit www.pdsbiotech.com
Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune® HPV, PDS01ADC and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, PDS01ADC and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Versamune® is a registered trademark of PDS Biotechnology Corporation.
Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com
Media Contact:
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: jmccargo@6degreespr.com
FAQ
What clinical data will be presented for PDSB's PDS01ADC at AACR 2025?
When and where will PDSB's PDS01ADC clinical data be presented?
What type of drug is PDS Biotech's PDS01ADC?
Who will present the clinical data for PDSB's PDS01ADC?
